Results 51 to 60 of about 9,980 (152)

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez, Emilio Lence, Juan C. Vázquez‐Ucha, Alejandro Beceiro, Concepción González‐Bello   +4 more
wiley   +1 more source

Clonal lineage and biofilm growth shape cefiderocol activity in Acinetobacter baumannii from oncology patients

Frontiers in Cellular and Infection Microbiology
IntroductionAcinetobacter baumannii is a leading cause of healthcare-associated infections in immunocompromised patients and frequently exhibits multidrug resistance.
Ilaria Cavallo, Francesca Sivori, Mauro Truglio, Massimo Francalancia, Elva Abril, Giorgia Fabrizio, Sara Petrolo, Francesca Maione, Grazia Prignano, Arianna Mastrofrancesco, Fulvia Pimpinelli, Enea Gino Di Domenico   +11 more
doaj   +1 more source

Evaluation of FilmArray Multiplex PCR Test Results in Bloodstream Infections in Oncological Patients

Journal of Clinical Laboratory Analysis, Volume 40, Issue 9, May 2026.
In this study conducted at an oncology hospital, BCID2 panel results for the rapid identification of microorganisms and resistance genes in positive blood culture samples were compared with conventional culture methods. The BCID2 panel provided faster results and showed a high correlation with traditional methods.
İpek Mumcuoğlu, Sevgi Şahin, Esra Tavukcu, Neşe İnan, Ayşe Semra Güreser, Serap Süzük Yıldız, Tuba Dal   +6 more
wiley   +1 more source

Physicochemical Stability of Aztreonam/Avibactam in Elastomeric Devices for Outpatient Parenteral Antimicrobial Therapy

Antibiotics
Background/Objectives: Outpatient Parenteral Antimicrobial Therapy (OPAT) programs provide a safe and cost-effective strategy for administering intravenous antimicrobials in the home setting.
Cristina Toro Blanch, Xabier Larrea Urtaran, Raquel Aguilar Salmerón, Alba Prat Riera, Laura Gómez, Anna Costa Pou, Beatriz Fernández-Rubio, Laura Herrera-Hidalgo, Carles Quiñones Ribas   +8 more
doaj   +1 more source

Genomic Insights Into Carbapenem‐Resistant Klebsiella pneumoniae in Pediatric Bloodstream Infections in Zhejiang, China (2019–2024)

Journal of Clinical Laboratory Analysis, Volume 40, Issue 10, May 2026.
The primary mechanism of carbapenem resistance identified in pediatric CRKP‐BSI strains was the production of Class B metalloenzymes. We report, for the first time, an outbreak of bloodstream infections in a neonatal ward caused by the dissemination of NDM‐1‐producing ST25 K. pneumoniae.
Mingming Zhou, Xiucai Zhang, Zhenjie Chen, Chao Fang, Shixing Liu, Jintao Xia, Yining Zhao, Chenmei Zhang, Hongqiang Shen   +8 more
wiley   +1 more source

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +1 more source

Struggle To Survive: the Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism

mSystems, 2020
Aztreonam-avibactam is a promising antimicrobial combination against multidrug-resistant organisms, such as carbapenemase-producing Enterobacterales. Resistance to aztreonam-avibactam has been found, but the resistance mechanism remains poorly studied ...
Ke Ma, Yu Feng, Alan McNally, Zhiyong Zong   +3 more
doaj   +1 more source

Emergence and Genomic Characterization of a Hypervirulent Klebsiella pneumoniae Isolate From a New Clone in Brazil

Microbiology and Immunology, Volume 70, Issue 5, Page 261-267, May 2026.
ABSTRACT Hypervirulent Klebsiella pneumoniae (hvKp) has emerged globally as a major public health concern, often associated with severe community‐acquired and healthcare‐associated human infections. Despite alerts from PAHO/WHO on convergent hvKp strains with multidrug resistance in Latin America, comprehensive data from Brazil, the region's largest ...
Carlos Henrique Camargo, Ana Beatriz Nascimento Costa, Amanda Yaeko Yamada, Daniel de Sena Miranda, Pedro Smith Pereira Ferraro, Andreia Rodrigues de Souza, Amanda Maria de Jesus Bertani, Karoline Rodrigues Campos, Marlon Benedito Nascimento Santos, Rafaela Mastrangelo Rissetti, Carolina Lechinski de Paula, Patrik Júnior de Lima Paz, Maria Solange Duarte Soares, Christiane Salvador, Giovanna de Pinho Pieri, Jorge Siguemassa Higa, Daniela dos Santos Souza, Márcio Garcia Ribeiro, Claudio Tavares Sacchi, Monique Ribeiro Tiba‐Casas, Geraldine Madalosso, Denise Brandao de Assis   +21 more
wiley   +1 more source

Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant Acinetobacter spp.

Microbiology Spectrum
Cefiderocol, a siderophore-cephalosporine conjugate antibiotic, shows promise as a therapeutic option for carbapenem-resistant (CR) Acinetobacter infections. While resistance has already been reported in A. baumannii, combination therapies with avibactam
Olivia Wong, Vyanka Mezcord, Christina Lopez, German Matias Traglia, Fernando Pasteran, Marisel R. Tuttobene, Alejandra Corso, Marcelo E. Tolmasky, Robert A. Bonomo, María Soledad Ramirez   +9 more
doaj   +1 more source

Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering

mBio, 2017
The emergence of Klebsiella pneumoniae carbapenemases (KPCs), β-lactamases that inactivate “last-line” antibiotics such as imipenem, represents a major challenge to contemporary antibiotic therapies.
Melissa D. Barnes, Marisa L. Winkler, Magdalena A. Taracila, Malcolm G. Page, Eric Desarbre, Barry N. Kreiswirth, Ryan K. Shields, Minh-Hong Nguyen, Cornelius Clancy, Brad Spellberg, Krisztina M. Papp-Wallace, Robert A. Bonomo   +11 more
doaj   +1 more source